GO:0071830 triglyceride-rich lipoprotein particle clearance: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071830 describes the receptor-mediated removal of triglyceride-rich lipoprotein particles from blood and degradation of their constituent parts.
• Triglyceride-rich lipoproteins include chylomicrons and very-low-density lipoproteins (VLDL), and their remnants are increasingly recognized as causal contributors to atherosclerotic cardiovascular disease [1,3].
• Key molecular players include apolipoproteins (APOB, APOC2, APOC3, APOE), lipoprotein lipase (LPL), hepatic receptors (LDLR, LRP1), and heparan sulfate proteoglycans (HSPGs) [1,6].
• Genetic and kinetic studies show that ANGPTL3 deficiency markedly accelerates triglyceride-rich lipoprotein clearance, validating this pathway as a therapeutic target.
• Impaired clearance leads to remnant cholesterol accumulation, a risk factor for cardiovascular disease in diabetes, obesity, and other metabolic disorders [2,7].
• CRISPR knockout, knock-in, and overexpression models enable causal dissection of genes controlling triglyceride-rich lipoprotein particle clearance [4,8].
Description
Triglyceride-rich lipoprotein particle clearance (GO:0071830) is the biological process by which triglyceride-rich lipoprotein particles are removed from the bloodstream via receptor-mediated endocytosis and their constituent parts are subsequently degraded. This process is central to postprandial and fasting lipid homeostasis and determines the residence time of atherogenic remnant particles in circulation [1,3]. The QuickGO definition specifies that the particle is removed from blood via receptor-mediated endocytosis and its constituent parts degraded, distinguishing it from related processes such as lipoprotein lipase-mediated lipolysis or intracellular lipid storage. Dysregulation of triglyceride-rich lipoprotein particle clearance is a well-established contributor to atherosclerotic cardiovascular disease (ASCVD) [1,3]. Elevated remnant cholesterol, a direct consequence of inefficient clearance, is associated with increased cardiovascular risk in diabetes, obesity, and other metabolic conditions [2,7]. The European Atherosclerosis Society consensus statement highlights triglyceride-rich lipoproteins and their remnants as causal factors in ASCVD and identifies clearance pathways as emerging therapeutic targets. Researchers studying GO:0071830 require robust experimental models to determine whether candidate genes causally regulate particle clearance. CRISPR-based knockout, point-mutation, knock-in, and overexpression cell models, combined with kinetic and biochemical assays, provide the tools to dissect this pathway at molecular resolution [4,8]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of triglyceride-rich lipoprotein particle clearance, its genes, mechanisms, disease relevance, and experimental approaches.
triglyceride-rich lipoprotein particle clearance At A Glance
| GO ID | GO:0071830 |
|---|---|
| GO term | triglyceride-rich lipoprotein particle clearance |
| Ontology | biological_process |
| Synonym | None |
| Major function | Receptor-mediated removal of triglyceride-rich lipoprotein particles from blood and degradation of their constituent parts |
| Definition source | QuickGO |
| Related particles | Chylomicrons, VLDL, and their remnants |
| Key receptors | LDLR, LRP1, HSPGs |
| Physiological role | Postprandial and fasting lipid homeostasis; prevention of remnant accumulation |
What Is GO:0071830?
Triglyceride-rich lipoprotein particle clearance is the process in which a triglyceride-rich lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts are degraded. This definition, from QuickGO (GO:0071830), encompasses the recognition of triglyceride-rich lipoprotein particles by cell-surface receptors, their internalization into cells, and the subsequent degradation of particle components such as triglycerides, cholesterol, and apolipoproteins. The process is distinct from lipolysis, which occurs in the circulation, and from intracellular lipid storage or oxidation pathways [1,6].
Why Is triglyceride-rich lipoprotein particle clearance Important in Cell Biology?
Triglyceride-rich lipoprotein particle clearance is critical because inefficient clearance leads to the accumulation of remnant cholesterol, which is a causal risk factor for atherosclerotic cardiovascular disease [1,3]. The European Atherosclerosis Society consensus statement identifies triglyceride-rich lipoproteins and their remnants as direct contributors to ASCVD, independent of LDL cholesterol. In diabetes and obesity, impaired clearance exacerbates dyslipidemia and increases cardiovascular risk [2,7]. Understanding the molecular mechanisms of clearance is therefore essential for developing targeted therapies and for interpreting genetic and kinetic studies [4,8].
• Determines the circulating residence time of atherogenic remnant particles.
• Directly linked to atherosclerotic cardiovascular disease risk [1,3].
• Impaired in insulin resistance, diabetes, and obesity [2,7].
• Regulated by apolipoproteins (APOC2, APOC3, APOE) and lipases (LPL) [1,8].
• ANGPTL3 deficiency accelerates clearance and lowers cardiovascular risk.
• Heparan sulfate proteoglycans facilitate particle uptake in liver.
• Postprandial triglyceride-rich lipoprotein composition influences clearance efficiency.
• Remnant cholesterol is a biomarker for cardiovascular risk in schizophrenia and other conditions.
• Therapeutic strategies targeting clearance are under active development.
• CRISPR models enable causal validation of candidate genes [4,8].
What Happens During triglyceride-rich lipoprotein particle clearance?
Lipolysis and Remnant Formation
In simple terms: Large triglyceride-rich particles are first broken down in the blood to smaller remnants.
Triglyceride-rich lipoproteins (chylomicrons and VLDL) undergo lipolysis by lipoprotein lipase (LPL), which hydrolyzes triglycerides and generates smaller remnant particles. This step is modulated by apolipoproteins such as APOC2 (activator) and APOC3 (inhibitor) [1,8]. The resulting remnants are enriched in cholesterol and apolipoprotein E (APOE), which facilitates their recognition by hepatic receptors.
Receptor Recognition and Binding
In simple terms: Remnant particles are recognized by specific receptors on liver cells.
Remnant particles are recognized by hepatic receptors including the LDL receptor (LDLR) and LDL receptor-related protein 1 (LRP1), as well as by heparan sulfate proteoglycans (HSPGs) [1,6]. APOE on the particle surface serves as a ligand for these receptors, while APOC3 can inhibit binding [1,8]. The interplay between these molecules determines the efficiency of particle capture.
Receptor-Mediated Endocytosis
In simple terms: The particle is taken up into the cell through a receptor-driven process.
Upon binding, the particle-receptor complex is internalized via clathrin-coated pits in a process requiring receptor-mediated endocytosis. This step is energy-dependent and involves endosomal trafficking. The QuickGO definition explicitly includes receptor-mediated endocytosis as the mechanism of removal from blood.
Intracellular Degradation
In simple terms: Inside the cell, the particle is broken down into its components.
After internalization, the particle is delivered to lysosomes where its constituent parts, including triglycerides, cholesterol esters, and apolipoproteins, are degraded. The degradation products are then either recycled or excreted. This step completes the clearance process as defined by GO:0071830.
Kinetic Regulation by ANGPTL3
In simple terms: ANGPTL3 acts as a brake on clearance by inhibiting lipases.
ANGPTL3 inhibits LPL and endothelial lipase, thereby slowing lipolysis and clearance of triglyceride-rich lipoproteins. Complete, lifelong ANGPTL3 deficiency in humans results in markedly accelerated triglyceride-rich lipoprotein clearance, as shown by kinetic studies. This demonstrates that ANGPTL3 is a key regulator of the clearance pathway.
Key Genes Involved in GO:0071830 triglyceride-rich lipoprotein particle clearance
The following genes and proteins are central to triglyceride-rich lipoprotein particle clearance, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Structural apolipoprotein of VLDL and chylomicrons | Target for knockout to study particle assembly and clearance |
| APOC2 | Activator of lipoprotein lipase | Loss-of-function causes hypertriglyceridemia; model for clearance defects |
| APOC3 | Inhibitor of lipoprotein lipase and hepatic uptake | Knockout lowers triglycerides and accelerates clearance [1,8] |
| APOE | Ligand for hepatic receptors (LDLR, LRP1) | Isoform-specific effects on remnant clearance |
| LPL | Hydrolyzes triglycerides in chylomicrons and VLDL | Deficiency causes severe hypertriglyceridemia |
| LDLR | Receptor for remnant and LDL uptake | Mutations cause familial hypercholesterolemia; affects clearance |
| LRP1 | Multifunctional receptor for remnant uptake | Mediates hepatic clearance of APOE-containing remnants |
| ANGPTL3 | Inhibits LPL and endothelial lipase | Deficiency accelerates clearance; therapeutic target |
| ANGPTL4 | Inhibits LPL | Regulates tissue-specific lipolysis and clearance |
| ANGPTL8 | Regulates ANGPTL3 activity | Modulates triglyceride-rich lipoprotein metabolism |
| GPIHBP1 | Endothelial platform for LPL | Required for LPL-mediated lipolysis |
| HSPG2 | Heparan sulfate proteoglycan | Facilitates hepatic remnant uptake |
| SDC1 | Syndecan-1, heparan sulfate proteoglycan | Involved in remnant binding and internalization |
| GPC1 | Glypican-1, heparan sulfate proteoglycan | Modulates clearance in liver |
| CREB3L3 | Transcription factor regulating lipid genes | Controls APOC2 and LPL expression |
| NR1H3 | Liver X receptor alpha | Regulates lipid metabolism and clearance |
| PPARA | Peroxisome proliferator-activated receptor alpha | Fibrate target; increases LPL and clearance |
| INSIG1 | Regulates SREBP processing | Indirectly affects lipid uptake and clearance |
How Is triglyceride-rich lipoprotein particle clearance Regulated?
Triglyceride-rich lipoprotein particle clearance is regulated at multiple levels. Transcriptional regulation by nuclear receptors such as PPARA and NR1H3 controls the expression of LPL, APOC2, and APOC3. Post-translational regulation by ANGPTL3, ANGPTL4, and ANGPTL8 modulates LPL activity and thus the rate of remnant formation and clearance [1,4]. Hormonal signals, including insulin, regulate LPL activity in adipose tissue and muscle, thereby influencing postprandial clearance [2,7]. In obesity and diabetes, altered adipokine profiles and insulin resistance impair clearance efficiency [2,5,7].
triglyceride-rich lipoprotein particle clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOC3 | Hypertriglyceridemia and cardiovascular risk | Knockout hepatocytes or mouse models to measure clearance kinetics |
| ANGPTL3 | Accelerated clearance and reduced ASCVD | Lifelong deficiency knock-in or knockout models |
| LDLR | Familial hypercholesterolemia | Point-mutation knock-in to mimic receptor defects |
| APOE | Alzheimer's disease and dyslipidemia | Isoform-specific knock-in models |
| LPL | Severe hypertriglyceridemia | Knockout or point-mutation cell models |
Atherosclerotic Cardiovascular Disease
Elevated remnant cholesterol due to impaired triglyceride-rich lipoprotein particle clearance is a causal risk factor for atherosclerotic cardiovascular disease [1,3]. The European Atherosclerosis Society consensus statement emphasizes that remnants directly promote atherogenesis. Genetic studies and clinical trials targeting ANGPTL3 and APOC3 support the causal role of this pathway.
Diabetes and Obesity
Insulin resistance in diabetes and obesity leads to overproduction of VLDL and impaired clearance of triglyceride-rich lipoproteins, contributing to diabetic dyslipidemia [2,7]. Postprandial triglyceride-rich lipoprotein composition is altered in obese adolescents, and adipokines influence clearance efficiency. These metabolic disturbances increase cardiovascular risk.
Schizophrenia and Metabolic Comorbidity
Patients with schizophrenia exhibit altered levels of triglyceride-rich lipoproteins and remnant cholesterol, as well as changes in apolipoproteins CII, CIII, and E, which are key regulators of clearance. These lipid abnormalities may contribute to the increased cardiovascular risk observed in this population.
From triglyceride-rich lipoprotein particle clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate clearance? | CRISPR knockout in hepatocyte cell lines (e.g., HepG2) |
| Does a specific mutation affect receptor binding? | Point-mutation knock-in of LDLR or LRP1 |
| Does overexpression accelerate clearance? | CRISPRa or lentiviral overexpression of APOE or LPL |
| How does ANGPTL3 deficiency affect kinetics? | Knock-in of loss-of-function ANGPTL3 variants |
| What is the role of HSPGs in uptake? | Knockout of HSPG2, SDC1, or GPC1 |
| Does APOC3 inhibition enhance clearance? | CRISPR knockout of APOC3 in primary hepatocytes [1,8] |
How to Study the triglyceride-rich lipoprotein particle clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Stable isotope kinetic study | Clearance rate of triglyceride-rich lipoproteins | In vivo human or animal studies |
| Lipoprotein fractionation | Triglyceride and cholesterol distribution | Clinical and preclinical lipid profiling |
| Fluorescent particle uptake | Receptor-mediated endocytosis | Cell-based clearance assays |
| CRISPR knockout screen | Genes affecting clearance | Discovery of novel regulators |
| RNA-seq | Transcriptional changes | Pathway analysis after genetic perturbation |
| Western blot | Protein expression of APOE, LPL, etc. | Validation of knockout or overexpression |
| Immunofluorescence | Cellular localization of receptors | Visualization of uptake machinery |
| Mass spectrometry | Apolipoprotein composition | Remnant characterization |
Kinetic Studies with Stable Isotopes
Stable isotope labeling combined with mass spectrometry can measure the production and clearance rates of triglyceride-rich lipoproteins in vivo. This approach has been used to demonstrate accelerated clearance in ANGPTL3 deficiency.
Lipoprotein Fractionation and Lipid Assays
Ultracentrifugation, gel filtration, and enzymatic assays quantify triglyceride and cholesterol levels in lipoprotein fractions, providing indirect measures of clearance efficiency [1,5].
Cellular Uptake Assays
Fluorescently labeled triglyceride-rich lipoprotein particles or remnants can be incubated with cells, and uptake measured by flow cytometry or microscopy to assess receptor-mediated endocytosis.
CRISPR Screening and Transcriptomics
Genome-wide CRISPR knockout screens coupled with RNA-seq can identify genes that modulate clearance when cells are challenged with triglyceride-rich lipoproteins [1,4].
How CRISPR Can Be Used to Study GO:0071830 triglyceride-rich lipoprotein particle clearance
Knockout
CRISPR knockout of candidate genes such as APOC3, ANGPTL3, or LDLR in hepatocyte cell lines or animal models enables direct testing of their role in triglyceride-rich lipoprotein particle clearance [1,4]. For example, ANGPTL3 knockout accelerates clearance in kinetic studies.
Point Mutation
Point-mutation knock-in can model naturally occurring variants, such as APOE isoforms or LDLR mutations, to dissect their effects on receptor binding and clearance efficiency. This approach is valuable for understanding genetic contributions to dyslipidemia.
Knock-in
Knock-in of tagged receptors (e.g., LDLR-GFP) allows real-time tracking of receptor trafficking and particle internalization. Knock-in of human APOC3 or ANGPTL3 variants into mouse models can replicate human clearance phenotypes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes such as LPL, APOE, or LDLR can enhance clearance and reverse hypertriglyceridemia in cell and animal models. Overexpression studies help establish sufficiency of a gene in promoting clearance.
How EDITGENE Supports triglyceride-rich lipoprotein particle clearance Research
Researchers studying triglyceride-rich lipoprotein particle clearance-related genes often need to determine whether a candidate gene is causally involved in particle removal or merely associated with altered lipid levels. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from knockout to precise point mutations and overexpression, supported by library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for triglyceride-rich lipoprotein particle clearance research.
Frequently Asked Questions About triglyceride-rich lipoprotein particle clearance
What is triglyceride-rich lipoprotein particle clearance?
It is the biological process (GO:0071830) by which triglyceride-rich lipoprotein particles are removed from blood via receptor-mediated endocytosis and degraded.
What genes are involved in triglyceride-rich lipoprotein particle clearance?
Key genes include APOB, APOC2, APOC3, APOE, LPL, LDLR, LRP1, ANGPTL3, and heparan sulfate proteoglycans such as HSPG2 and SDC1 [1,4,6].
How is triglyceride-rich lipoprotein particle clearance regulated?
It is regulated by apolipoproteins, lipases, ANGPTL proteins, nuclear receptors, and insulin signaling [1,4].
What diseases are associated with impaired clearance?
Impaired clearance is linked to atherosclerotic cardiovascular disease, diabetes, obesity, and metabolic abnormalities in schizophrenia [1,2,7,8].
What is the role of ANGPTL3 in clearance?
ANGPTL3 inhibits lipoprotein lipase, and its deficiency accelerates triglyceride-rich lipoprotein clearance.
How can CRISPR be used to study this process?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of genes in clearance pathways [1,4].
What are remnant lipoproteins?
Remnant lipoproteins are the smaller particles formed after partial lipolysis of triglyceride-rich lipoproteins; they are cleared by hepatic receptors [1,3].
Why is remnant cholesterol important?
Elevated remnant cholesterol is a causal risk factor for atherosclerotic cardiovascular disease [1,3].
What cell models are used to study clearance?
Hepatocyte cell lines (e.g., HepG2), primary hepatocytes, and macrophage models are commonly used [1,6].
What methods measure clearance?
Stable isotope kinetics, lipoprotein fractionation, fluorescent uptake assays, and CRISPR screens are standard methods [4,6].
Conclusion
Triglyceride-rich lipoprotein particle clearance (GO:0071830) is a fundamental biological process that controls the removal of atherogenic remnant particles from circulation. Its dysregulation is causally linked to cardiovascular disease, diabetes, and obesity, making it a high-priority research area [1,3,7]. Advances in CRISPR-based models and kinetic methods have clarified the roles of key genes such as ANGPTL3, APOC3, and LDLR [4,8]. EDITGENE provides the tools needed to dissect this pathway, from knockout and knock-in cell models to library screening and bioinformatics. By enabling precise genetic perturbations, researchers can accelerate the translation of clearance biology into therapeutic strategies.
References
- 1. Ginsberg HN et al.. 2021. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.. Eur Heart J 42(47):4791-4806 PMID: 34472586
- 2. Tchernof A et al.. 2013. Pathophysiology of human visceral obesity: an update.. Physiol Rev 93(1):359-404 PMID: 23303913
- 3. Duran EK et al.. 2021. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease.. Clin Chem 67(1):183-196 PMID: 33409533
- 4. Fappi A et al.. 2025. Effect of complete, lifelong ANGPTL3 deficiency on triglyceride-rich lipoprotein kinetics.. Cell Rep Med 6(6):102152 PMID: 40446802
- 5. García-Rodríguez S et al.. 2024. Interplay of Postprandial Triglyceride-Rich Lipoprotein Composition and Adipokines in Obese Adolescents.. Int J Mol Sci 25(2) PMID: 38256185
- 6. Bishop JR et al.. 2008. Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism.. Curr Opin Lipidol 19(3):307-13 PMID: 18460924
- 7. Ginsberg HN et al.. 2026. Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.. Circ Res 138(12):e327267 PMID: 42241511
- 8. Wang J et al.. 2024. Triglyceride-rich lipoprotein, remnant cholesterol, and apolipoproteins CII, CIII, and E in patients with schizophrenia.. J Lipid Res 65(7):100577 PMID: 38879166
